The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Allergen-Induced Asthmatic Responses Modified by a GATA3-Specific DNAzyme
Open accessAbstract
BACKGROUND: The most prevalent phenotype of asthma is characterized by eosinophil-dominated inflammation that is driven by a type 2 helper T cell (Th2). Therapeutic targeting of GATA3, an important transcription factor of the Th2 pathway, may be beneficial. We evaluated the safety and efficacy of SB010, a novel DNA enzyme (DNAzyme) that is able to cleave and inactivate GATA3 messenger RNA (mRNA). METHODS: We conducted a randomized, double-blind, placebo-controlled, multicenter clinical trial of SB010 involving patients who had allergic asthma with sputum eosinophilia and who also had biphasic early and late asthmatic responses after laboratory-based allergen provocation. A total of 40 patients could be evaluated; 21 were assigned to receive 10 mg of SB010, and 19 were assigned to receive placebo, with each study drug administered by means of inhalation once daily for 28 days. An allergen challenge was performed before and after the 28-day period. The primary end point was the late asthmatic response as quantified by the change in the area under the curve (AUC) for forced expiratory volume in 1 second (FEV1). RESULTS: After 28 days, SB010 attenuated the mean late asthmatic response by 34%, as compared with the baseline response, according to the AUC for FEV1, whereas placebo was associated with a 1% increase in the AUC for FEV1 (P=0.02). The early asthmatic response with SB010 was attenuated by 11% as measured by the AUC for FEV1, whereas the early response with placebo was increased by 10% (P=0.03). Inhibition of the late asthmatic response by SB010 was associated with attenuation of allergen-induced sputum eosinophilia and with lower levels of tryptase in sputum and lower plasma levels of interleukin-5. Allergen-induced levels of fractional exhaled nitric oxide and airway hyperresponsiveness to methacholine were not affected by either SB010 or placebo. CONCLUSIONS: Treatment with SB010 significantly attenuated both late and early asthmatic responses after allergen provocation in patients with allergic asthma. Biomarker analysis showed an attenuation of Th2-regulated inflammatory responses. (Funded by Sterna Biologicals and the German Federal Ministry of Education and Research; ClinicalTrials.gov number, NCT01743768.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Global strategy for asthma management and prevention: GINA executive summary
Bateman, E. D., Hurd, S. S., Barnes, P. J., Bousquet, J., Drazen, J. M., FitzGerald, M., Gibson, P., Ohta, K., O'Byrne, P., Pedersen, S. E., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00138707 · Cited by 3,203
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200406-710st · Cited by 3,203
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.1.ats11-99 · Cited by 2,467
Asthma phenotypes: the evolution from clinical to molecular approaches
Wenzel, S. E. (2012) · Nature Medicine · doi:10.1038/nm.2678 · Cited by 2,412
Pavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Self-citationMepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Haldar, P., Brightling, C. E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., Marshall, R. P., Bradding, P., Green, R. H., Wardlaw, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808991 · Cited by 1,871
T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma
Woodruff, P. G., Modrek, B., Choy, D. F., Jia, G., Abbas, A. R., Ellwanger, A., Arron, J. R., Koth, L. L., & Fahy, J. V. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200903-0392oc · Cited by 1,803
Lebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514
Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
Nair, P., Pizzichini, M. M. M., Kjarsgaard, M., Inman, M. D., Efthimiadis, A., Pizzichini, E., Hargreave, F. E., & O'Byrne, P. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805435 · Cited by 1,356
Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,320
Innate and adaptive immune responses in asthma
Holgate, S. T. (2012) · Nature Medicine · doi:10.1038/nm.2731 · Cited by 902
Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses
Gauvreau, G. M., O'Byrne, P. M., Boulet, L.-P., Wang, Y., Cockcroft, D., Bigler, J., FitzGerald, J. M., Boedigheimer, M., Davis, B. E., Dias, C., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402895 · Cited by 789
Fahy, J. V., Fleming, H. E., Wong, H. H., Liu, J. T., Su, J. Q., Reimann, J., Fick, R. B., & Boushey, H. A. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.6.9196082 · Cited by 713
The Transcription Factor GATA3 Is Essential for the Function of Human Type 2 Innate Lymphoid Cells
Mjösberg, J., Bernink, J., Golebski, K., Karrich, J. J., Peters, C. P., Blom, B., te Velde, A. A., Fokkens, W. J., van Drunen, C. M., & Spits, H. (2012) · Immunity · doi:10.1016/j.immuni.2012.08.015 · Cited by 636
Wenzel, S., Wilbraham, D., Fuller, R., Getz, E. B., & Longphre, M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61600-6 · Cited by 588
Cockcroft, D. W., & Murdock, K. Y. (1987) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(87)90204-1 · Cited by 490
Petsky, H. L., Cates, C. J., Lasserson, T. J., Li, A. M., Turner, C., Kynaston, J. A., & Chang, A. B. (2012) · Thorax · doi:10.1136/thx.2010.135574 · Cited by 338
Severe asthma: from characteristics to phenotypes to endotypes
Wenzel, S. (2012) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2011.03929.x · Cited by 336
Eosinophils in the Spotlight: Eosinophilic airway inflammation in nonallergic asthma
Brusselle, G. G., Maes, T., & Bracke, K. R. (2013) · Nature Medicine · doi:10.1038/nm.3300 · Cited by 316
A Randomized, Controlled, Phase 2 Study of AMG 317, an IL-4Rα Antagonist, in Patients with Asthma
Corren, J., Busse, W., Meltzer, E. O., Mansfield, L., Bensch, G., Fahrenholz, J., Wenzel, S. E., Chon, Y., Dunn, M., Weng, H. H., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200909-1448oc · Cited by 299
Th2 cells and GATA-3 in asthma: new insights into the regulation of airway inflammation
Ray, A., & Cohn, L. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8204 · Cited by 273
Cockcroft, D. W., Murdock, K. Y., Kirby, J., & HARGREAVE, F. E. (1987) · PubMed · doi:10.1164/arrd.1987.135.1.264 · Cited by 263
IL-13 in asthma and allergic disease: Asthma phenotypes and targeted therapies
Ingram, J. L., & Kraft, M. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.06.034 · Cited by 253
Human asthma phenotypes: from the clinic, to cytokines, and back again
Bhakta, N. R., & Woodruff, P. G. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01032.x · Cited by 186
Inhaled allergen bronchoprovocation tests
Diamant, Z., Gauvreau, G. M., Cockcroft, D., Boulet, L., Sterk, P. J., de Jongh, F. H., Dahlén, B., & O’Byrne, P. M. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.08.023 · Cited by 116
Cho, E.-A., Moloney, F. J., Cai, H., Au-Yeung, A., China, C., Scolyer, R. A., Yosufi, B., Raftery, M. J., Deng, J. Z., Morton, S. W., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62166-7 · Cited by 114
Effective prevention and therapy of experimental allergic asthma using a GATA-3–specific DNAzyme
Sel, S., Wegmann, M., Dicke, T., Sel, S., Henke, W., Yildirim, A. Ö., Renz, H., & Garn, H. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.12.1175 · Cited by 107
Self-citationClinical utility of asthma biomarkers: from bench to bedside
der Zee, A. H. M., Vijverberg, S. J. H., Hilvering, B., Raaijmakers, Lammers, & Koenderman, L. (2013) · Biologics · doi:10.2147/btt.s29976 · Cited by 105
Peripheral deposition of α1‐protease inhibitor using commercial inhalation devices
Brand, P., Beckmann, H., Enriquez, M. M., Meyer, T. S., Müllinger, B., Sommerer, K., Weber, N., Weuthen, T., & Scheuch, G. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00096802 · Cited by 70
Repeatability of allergen-induced airway inflammation
Gauvreau, G. M., Watson, R. M., Rerecich, T., et al. (1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70115-6 · Cited by 60
Trials and tribulations in identifying new biologic treatments for asthma
Holgate, S. T. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.02.003 · Cited by 49
Santiago, F. S., & Khachigian, L. M. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100272 · Cited by 46
Allergen-induced Airway Inflammation and Its Therapeutic Intervention
O’Byrne, P. M. (2009) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2009.1.1.3 · Cited by 41
GATA‐3 represses gp91phox gene expression in eosinophil‐committed HL‐60‐C15 cells
Sadat, M., Kumatori, A., Suzuki, S., Yamaguchi, Y., Tsuji, Y., & Nakamura, M. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01182-x · Cited by 14
No DL1 Notch ligand? GATA be a mast cell
Winandy, S., & Brown, M. A. (2007) · Nature Immunology · doi:10.1038/ni0807-796 · Cited by 11
Cited by
Lambrecht, B. N., Hammad, H., & Fahy, J. V. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.018 · Cited by 1,039
Current and emerging therapeutic targets for IBD
Neurath, M. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.208 · Cited by 691
Holgate, S. T., Wenzel, S., Postma, D. S., Weiss, S. T., Renz, H., & Sly, P. D. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.25 · Cited by 652
Self-citationTH2 cell development and function
Walker, J. A., & McKenzie, A. N. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.118 · Cited by 632
The Asthma–COPD Overlap Syndrome
Postma, D. S., & Rabe, K. F. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1411863 · Cited by 548
Metadata
- Authors
- Krug, N., Hohlfeld, J. M., Kirsten, A.-M., Kornmann, O., Beeh, K. M., Kappeler, D., Korn, S., Ignatenko, S., Timmer, W., Rogon, C., Zeitvogel, J., Zhang, N., Bille, J., Homburg, U., Turowska, A., Bachert, C., Werfel, T., Buhl, R., Renz, J., Garn, H., & Renz, H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-21
- Volume
- 372
- Issue
- 21
- Pages
- 1987-1995
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W242058159
- Cited by
- 321
- References
- 36
- FWCI
- 34.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.